Intravitreal injections are a routine and highly effective treatment used to stabilize or restore vision in patients with diabetic eye disease, age-related macular degeneration, and retinal vein occlusions. In most cases, these injections help prevent further vision loss and can even improve eyesight when administered appropriately.
Omar Krad, MD, shares his practical approach to cataract surgery in patients with wet macular degeneration. This case involves a diabetic, hyperopic patient with vision limited to counting…
Charles C. Wykoff, MD, highlights both the success and the limitations of current treatments for wet AMD. While anti-VEGF therapies are effective at controlling bleeding and leakage in…
Diabetic macular edema (DME) is a leading cause of vision loss in people with diabetes. It occurs when long-term high blood sugar damages retinal blood vessels, causing them…
Sean Adrean, MD, Retina Consultants of Orange County, describes results from a post hoc analysis of the Phase 2/3 PHOTON trial investigating the impact of baseline visual acuity…
Diana Do, MD, professor of ophthalmology and vice chair for clinical affairs, Byers Eye Institute, Stanford University, discusses real-world data presented at the American Academy of Ophthalmology showing…
The video features an interview with Tien Y. Wong, MD, PhD, Tsinghua University, about a post-hoc analysis from the PULSAR randomized trial evaluating high-dose aflibercept (8 mg) in…
Wet age-related macular degeneration (AMD) is a chronic, progressive eye disease marked by abnormal blood vessel growth beneath the retina. These fragile vessels can leak fluid or blood…
Deepak Sambhara, MD, Eye Clinic of Wisconsin, discusses results from a post hoc analysis of the Phase 2/3 PHOTON trial investigating the impact of central retinal thickness on…
Anti-VEGF injections are a common treatment for wet age-related macular degeneration (AMD), aimed at preserving or even improving vision by stopping abnormal blood vessel growth under the macula.…
In this episode of RetinUp, hosts John Kitchens, MD, and Scott Krzywonos discuss the new CMS GLOBE Model, a Medicare Part B drug pricing demonstration project, and the…
